Life Sciences

  • April 13, 2026

    Texas GLP-1 Compounder Caused Mom's Death, Family Says

    A Houston compounding pharmacy misled consumers by marketing its weight loss and diabetes drugs as safe and pharmaceutical-grade while selling contaminated medicines, a deceased Texas woman's family claims in a wrongful death lawsuit, alleging the drugs led to the woman's death. 

  • April 13, 2026

    11th Circ. Backs FDA's Ban Over Drug Tester's Conviction

    The Eleventh Circuit on Monday backed a U.S. Food and Drug Administration order barring a former pharmaceutical worker from future interaction with the agency after she was convicted of lying during an investigation of her company, rejecting her bid for judicial review of the decision.

  • April 13, 2026

    Chamber, Other Biz Groups Back Insulin Cos. At High Court

    The U.S. Chamber of Commerce and other business groups urged the U.S. Supreme Court to take up an appeal from Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing the Second Circuit's revival of an antitrust suit risks opening up liability just for trade group membership.

  • April 13, 2026

    Ex-Med Spa Workers Settle Conn. Poaching Claims

    A Connecticut medical spa has settled a state court lawsuit accusing two former employees of luring clients and a colleague to a similar facility less than six miles away, court records show.

  • April 10, 2026

    Medtronic Can't Ax $382M Trial Loss, Applied Medical Says

    Applied Medical Resources Corp. has urged a California federal court to reject Medtronic Inc.'s attempt to ditch its roughly $382 million antitrust trial loss, arguing that Medtronic is simply repeating "erroneous legal arguments this court already rejected."

  • April 10, 2026

    Chest Binders Become Latest Front In Anti-Trans Litigation

    Chest binders — medical devices that can be used by individuals experiencing gender dysphoria or who want a more gender-neutral alternative to bras — have emerged as the newest target in an unfolding regulatory and legal climate that transgender advocates describe as an overtly partisan political attack against a type of product that the U.S. Food and Drug Administration has deemed the least risky.

  • April 10, 2026

    Chinese Scholar Gets Time Served For Smuggling E. Coli DNA

    A Chinese postdoctoral research associate at Indiana University was sentenced to time served on Wednesday by an Indiana federal judge, spending more than four months in custody on smuggling charges for shipping an E. coli sample from China into the U.S. and lying about it when questioned by U.S. Customs and Border Protection agents. 

  • April 10, 2026

    NJ Justices Won't Review Beasley Allen's DQ From Talc Cases

    The New Jersey Supreme Court has declined to review a lower court's order booting the Beasley Allen Law Firm from multicounty litigation in the Garden State over Johnson & Johnson's talcum powder, according to an order made public Friday.

  • April 10, 2026

    Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit

    A federal judge Friday allowed abortion medication manufacturers GenBioPro Inc. and Danco Laboratories to intervene in litigation brought by the states of Texas and Florida seeking to undo a slew of federal regulations concerning the abortion drug mifepristone.

  • April 10, 2026

    Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea

    An Indiana federal judge declined to toss a proposed class action claiming Elevance Health Inc. illegally denied coverage for a GLP-1 weight loss medication that was prescribed to treat sleep apnea, ruling that the insurance company is the right party to answer to the allegations at play.

  • April 10, 2026

    Taxation With Representation: Goodwin, CMS, Wilson Sonsini

    In this week's Taxation With Representation, Gilead Sciences Inc. acquires clinical-stage biotechnology company Tubulis GmbH, private equity firm Court Square Capital Partners closes a multibillion-dollar fund and Neurocrine Biosciences Inc. buys rare-disease drugmaker Soleno Therapeutics Inc.

  • April 10, 2026

    Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict

    Illinois jurors on Friday slapped another $17 million in punitive damages atop the $53 million they awarded the previous afternoon to four mothers who accused Abbott Laboratories of selling preterm infant formula that contributed to a serious and often fatal gut condition their babies developed.

  • April 09, 2026

    Yale Medical School Can't Nix Fraudulent Insemination Suit

    Yale can't escape a negligence suit by onetime patients alleging its former fertility doctor secretly inseminated them with his own sperm, after a Connecticut judge said that a letter from an anonymous doctor, which is mandated by law to support their claims, met the statutory requirements.

  • April 09, 2026

    Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit

    An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.

  • April 09, 2026

    Abbott Hit With $53M Verdict Over Baby Formula Harms

    A Cook County jury on Thursday awarded a total of $53 million in damages to four mothers claiming Abbott Laboratories' preterm baby formula contributed to their babies' development of a serious and often fatal gut condition, in the first of such claims to go to trial in Illinois.

  • April 09, 2026

    Split 4th Circ. Backs West Virginia Schoolchildren Vax Law

    A split Fourth Circuit panel struck down an order barring West Virginia from applying a compulsory vaccination law to a student whose parents alleged the law violates her religious rights, ruling the law serves the state's interest in reducing the spread of infectious diseases.

  • April 09, 2026

    Merck Beats 295 Zostavax Suits Over Missed Deadlines

    A Pennsylvania federal judge has tossed 295 cases against Merck & Co. Inc. in the multidistrict litigation alleging its Zostavax shingles vaccine caused the disease, with the court reasoning that the plaintiffs' inactivity doomed the cases.

  • April 09, 2026

    McKinsey Settles Liability For $125M In Purdue Ch. 11

    Consulting firm McKinsey & Co. has agreed to pay $125 million to former client Purdue Pharma LP to settle potential claims related to its work advising Purdue on the sale and marketing of opioids, tying up another loose end in the nearly seven-year-old Chapter 11 case.

  • April 09, 2026

    Nonprofit Insurer Wants To Seek AstraZeneca Claims Revival

    EmblemHealth asked a Massachusetts federal judge to let it seek First Circuit intervention against a decision that cut in half its proposed class action accusing AstraZeneca unit Alexion of using sham patents to protect blood disorder treatment Soliris from biosimilar rivals.

  • April 09, 2026

    Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'

    A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed the group's religious freedom.

  • April 09, 2026

    Abiomed Can't Escape Blood Pump Patent Case

    A Massachusetts federal judge has refused to let a Johnson & Johnson MedTech subsidiary dodge claims that it infringed a blood pump patent, the latest event in a wider legal battle launched against it by a unit of Swedish medical device company Getinge AB.

  • April 09, 2026

    Ecolab Says Personal Injury Law Firm Holding Back $148K

    Ecolab and its self-funded employee benefit plan have accused a North Carolina personal injury firm of withholding around $148,000 in settlement funds the food safety company says it's owed for covering a worker's medical bills after a car accident.

  • April 09, 2026

    Ex-Pharmacy Director Denies Using Trade Secrets At New Job

    A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.

  • April 09, 2026

    US Again Urges High Court To Back Drug Price Program

    The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate. 

  • April 08, 2026

    Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation

    A Federal Circuit panel expressed frustration with attorneys from both Purdue Pharma LP and generic-drug maker Accord Healthcare Inc. Wednesday as it tried to navigate whether the Delaware district court order invalidating Purdue's abuse-deterrence patent was explicit enough.

Expert Analysis

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.